Cancer second largest killer in India: Oncology report

There were 1.17 million new cancer cases in India whereas 6,75,000 deaths in 2013

cancer

Cancer kills the most number of people in India after heart disease, says Global Burden of Cancer report 2013 published by JAMA Oncology.

According to the report, there were 1.17 million new cancer cases in India whereas 6,75,000 deaths in 2013. There is a sharp increase from the figures from 1990 when the numbers registered were 6,24,000 cancer cases and 4,26,000 deaths. Late diagnosis of cancer in advanced stages leads to late treatment, causing more deaths in India.

In 2013 there were 14.9 million incident cancer cases, 8.2 million deaths, and 196.3 million DALYs. Prostate cancer was the leading cause for cancer incidence (1.4 million) for men and breast cancer for women (1.8 million). Tracheal, bronchus, and lung (TBL) cancer was the leading cause for cancer death in men and women, with 1.6 million deaths. For men, TBL cancer was the leading cause of DALYs (24.9 million). For women, breast cancer was the leading cause of DALYs (13.1 million). Age-standardized incidence rates (ASIRs) per 100 000 and age-standardized death rates (ASDRs) per 100 000 for both sexes in 2013 were higher in developing vs developed countries for stomach cancer (ASIR, 17 vs 14; ASDR, 15 vs 11), liver cancer (ASIR, 15 vs 7; ASDR, 16 vs 7), esophageal cancer (ASIR, 9 vs 4; ASDR, 9 vs 4), cervical cancer (ASIR, 8 vs 5; ASDR, 4 vs 2), lip and oral cavity cancer (ASIR, 7 vs 6; ASDR, 2 vs 2), and nasopharyngeal cancer (ASIR, 1.5 vs 0.4; ASDR, 1.2 vs 0.3). Between 1990 and 2013, ASIRs for all cancers combined (except nonmelanoma skin cancer and Kaposi sarcoma) increased by more than 10% in 113 countries and decreased by more than 10% in 12 of 188 countries.

Cancer poses a major threat to public health worldwide, and incidence rates have increased in most countries since 1990. The trend is a particular threat to developing nations with health systems that are ill-equipped to deal with complex and expensive cancer treatments, says report.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

BusinessWire India.com - Healthcare & biotechnology

Bwi-logo

REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy

Saturday, 25 Feb 2017   |   Celgene

Business Wire India Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:

Piramal Enterprises Limited and Ivanhoé Cambridge Announce Partnership

Thursday, 23 Feb 2017   |   Piramal Enterprises Limited

Business Wire India Ivanhoé Cambridge to allocate an initial US$250m PEL will co-invest between

Bangalore-based Start-up, Cardiotrack, a Fast Growing Predictive Diagnostic

Wednesday, 22 Feb 2017   |   Cardiotrack

Business Wire India Bangalore-based start-up, Cardiotrack, which provides best-in-class predictive diagnosis

BusinessWire India.com - Pharmaceutical

Bwi-logo

REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy

Saturday, 25 Feb 2017   |   Celgene

Business Wire India Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:

Piramal Enterprises Limited and Ivanhoé Cambridge Announce Partnership

Thursday, 23 Feb 2017   |   Piramal Enterprises Limited

Business Wire India Ivanhoé Cambridge to allocate an initial US$250m PEL will co-invest between

BusinessWire India.com - Medical Devices

Bwi-logo

REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy

Saturday, 25 Feb 2017   |   Celgene

Business Wire India Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:

Bangalore-based Start-up, Cardiotrack, a Fast Growing Predictive Diagnostic

Wednesday, 22 Feb 2017   |   Cardiotrack

Business Wire India Bangalore-based start-up, Cardiotrack, which provides best-in-class predictive diagnosis

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email

X